MIGS Devices
Your MIGS Choice Matters
MIGS Devices
Your MIGS Choice Matters
Hydrus® Microstent
The first and only MIGS device to report significant safety and effectiveness outcomes from a pivotal trial at 5 years.1,2
Alcon Experience Academy
For relevant training content from industry thought leaders
References:
1. Ahmed IIK, et al. Long-term outcomes from the HORIZON randomized trial for Schlemm’s Canal microstent in combination cataract and glaucoma surgery. Ophthalmology. 2022;129(7):742-751.
2. NIH. Safety & effectiveness study of the Hydrus Microstent for lowering IOP in glaucoma patients undergoing cataract surgery (HORIZON). ClinTrials.gov (NCT01539239).
Please refer to relevant product direction for use for list of indications, contraindications and warnings.
To be distributed to healthcare professionals only.
This Site may contain information on worldwide products and services, not all of which are available in Singapore.